Comparison of the Outcome of Treatment With Silymarin or N-Aceylcysteine in Patients Taking Anti-Tuberculous Drugs for Tuberculosis at a Tertiary Care Hospital , Karachi

Launched by LIAQUAT NATIONAL HOSPITAL & MEDICAL COLLEGE · Jul 4, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how two different medicines, silymarin and N-acetylcysteine, help protect the liver in patients who are being treated for tuberculosis (TB) with anti-tuberculosis drugs. Sometimes, these TB medicines can cause liver damage, so the study aims to find out which of these two treatments works better to prevent or reduce that liver injury.

The study is open to adults aged 40 to 80 years who have just been diagnosed with tuberculosis and have not yet started any TB treatment. People with certain health issues like liver disease, HIV, viral hepatitis, or a history of alcohol use will not be able to join. If you participate, you will receive either silymarin or N-acetylcysteine while you take your TB medicines, and doctors will check your liver function through blood tests before and during treatment to see how well your liver is doing. This trial is still in the early stages and has not started enrolling patients yet.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients presenting with tuberculosis and previously not on any anti-tuberculous drugs, between 40-80 years of age
• • either gender.
• Exclusion Criteria:
• • History of malignancy.
• • Patients with history of seropositive, seronegative, connective tissue disorder or vasculitis, congestive cardiac failure.
• • Patients with history of alcohol use.
• • Discontinuation of drug due to other adverse effects except hepatotoxicity.
• • Inadequate date of laboratory testing at baseline or 2 to 4 weeks after treatment initiation.
• • Cases with human immunodeficiency virus (HIV) co-infection, viral hepatitis, or suspected mal absorption (e.g., gastrointestinal disease or diarrhea).
• • Chronic liver disease, COPD, asthma, myocardial infarction, chronic kidney disease and stroke.